# Enantioselective 1,4-additions of CIMeAl(CH=CHR) (R = alkyl, alkenyl, Ph) to cyclohexenones: supporting data

D. Willcox, S. Woodward and A. Alexakis

General: All reactions were carried out under an argon atmosphere in flame or oven-dried glassware. Tetrahydrofuran and diethyl ether were benzophenone freshly distilled from sodium ketyl. Dichloroalane bis(tetrahydrofuran) was prepared by literature methods (ref. 6 in main paper) and stored under inert atmospheres; its purity determined by evolved  $H_2$  volume on aqueous quench of small samples (<0.1 q). Samples of  $A|HC|_2 \cdot (THF)_2$  were normally weighed under inert atmosphere, but larger quantities could be handled promptly in air if necessary. All alkynes and commercially available enones were distilled prior to use. All other commercially available compounds were used without further purification. 3-Ethylcyclohex-2-en-1-one<sup>1</sup> was prepared according to literature procedure. Phosphoramidates and SimplePhos Ligands prepared according to literature procedures.<sup>2</sup> Flash column chromatography was carried out using Davisil silica gel 60 (0.035 - 0.070 mm particle size). Thin layer chromatography was carried out using Merck F<sub>254</sub> aluminium backed-silica-plates.

Proton (400.1 MHz) and carbon-13 (100.6 MHz) NMR spectra were recorded on Bruker DPX400, AV400 or AV(III)400 instruments; assignments H<sup>n</sup> refer to protons attached to carbon C<sup>n</sup> in the numbering schemes provided. Numbering was assigned using ChemDraw Ultra 12 and used for NMR assignment purposes only. Chemical shifts are quoted as parts per million and referenced to  $CHCl_3$  (7.26 ppm for <sup>1</sup>H and 77.1 ppm for <sup>13</sup>C nuclei).<sup>3</sup> Carbon-13 NMR spectra were recorded with broadband proton decoupling. Infra-red spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer. Melting points were measured on a Gallenkamp melting point apparatus and are uncorrected. Mass spectrometry was carried out using either a Bruker MicroTOF or a Micromass AutoSpec instrument. GC analysis was carried out using a Varian 3400 with CP400 autosampler instrument and HPLC assay was carried out using a Varian ProStar with UV detector. Optical rotation was recorded using an ADP 440 machine with the  $[\alpha]_D$  being guoted at 25 °C.

**General procedure 1:** volatile alkyne hydroalumination and conjugate addition

A 1.5 mL vial (glass screw cap vial, 854171, Supelco) was charged with decamethylzirconocene dichloride (21.6 mg, 0.05 mmol, 0.05 equiv.) and dichloroalane *bis*(tetrahydrofuran) (340 mg, 1.40 mmol, 1.4 equiv.) under an inert atmosphere. Neat alkyne (1.00 mmol) and tetrahydrofuran (1.0 mL) were injected through the septum (9mm AG3 CenterGuide, CR246713, Varian) and mixture was heated for 2 h at 80 °C. The solution was transferred to a flame-dried Schlenk tube and solvent removed in vacuo and replaced with toluene (1.0 mL). To this was added methyllithium (330  $\mu$ L, 0.65 mmol, 2 M in diethyl ether) and the mixture stirred for 30 min. In a Radleys carousel tube, CuTC (9.50 mg, 0.05 mmol) and ligand L2 (47.9 mg, 0.075 mmol) were dissolved in tbutylmethyl ether (1.0 mL) and stirred for 15 mins. The alane mixture was transferred to the copper mixture *via* syringe and enone (0.5 mmol) in toluene (0.5 mL) was added over 0.5 h. The reaction was stirred for a further 0.5 h at 25 °C and then quenched with water and HCl (1 M). The organic layer was separated and the aqueous phase was extracted with dichloromethane (3 x 5 mL). The combined organic phases were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude was purified by flash chromatography (pentane/diethyl ether 4:1).

**General procedure 2:** Zirconium-catalysed hydroalumination and conjugate addition (neat conditions)

A dried Schlenk tube was charged dichloroalane bis(tetrahydrofuran) (158 mg, 0.65 mmol), decamethylzirconocene dichloride (14.0 mg, 0.03 mmol) and 1-octyne (134 µL, 1.40 mmol) and the mixture melted at 80 °C for 1.5 h. The excess alkyne was removed under vacuum (0.1 mmHg). The resulting alane was diluted with toluene (1.0 mL) and methyllithium added (330 µL, 0.65 mmol, 2M in diethyl ether) and the mixture stirred for 30 min. In a Radleys carousel tube, CuTC (9.50 mg, 0.05 mmol) and ligand L2 (47.9 mg, 0.075 mmol) were and stirred for 15 mins in tbutylmethyl ether (1.0 mL). The previously prepared alane mixture was transferred to the CuTC/L2 catalyst via syringe and enone (0.5 mmol) in toluene (0.5 mL) was added over 0.5 h. The reaction was stirred for a further 0.5 h at 25 °C and then guenched with water and HCl (1 M). The organic layer was separated and the aqueous phase was extracted with dichloromethane (3 x 5 mL). The combined organic phases were dried  $(Na_2SO_4)$ , filtered, and concentrated. The crude was purified by flash chromatography (pentane/diethyl ether 4:1).

## (S)-(E)-3-(oct-1-en-1-yl)cyclohexanone (2a)<sup>4</sup>



Prepared according to general procedure 2 from 1-octyne (134  $\mu$ L, 1.40 mmol) and cyclohexenone (48  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 88% e.e. (67.7 mg, 65%, 0.325 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.56.

<sup>1</sup>**H** NMR  $\delta_{\text{H}}$ : 0.83 (3H, t, J = 7.0 Hz,  $C^{15}$ **H**<sub>3</sub>), 1.20–1.32 (8H, m,  $C^{11}$ **H**<sub>2</sub>- $C^{14}$ **H**<sub>2</sub>), 1.39–1.49 (1H, m, *c*-hex), 1.58–1.69 (1H, m, *c*-hex), 1.83–1.92 (1H, m, *c*-hex), 1.91–2.02 (3H, m, *c*-hex), 2.11–2.17 (1H, m, *c*-hex), 2.19–2.25 (1H, m, *c*-hex), 2.26–2.44 (3H, m, *c*-hex and  $C^{10}$ **H**<sub>2</sub>), 5.31 (1H, dd, J = 16.0, 6.0 Hz,  $C^{8}$ **H**), 5.38 (1H, dt, J = 16.0, 6.5 Hz,  $C^{9}$ **H**).

<sup>13</sup>**C** NMR  $\delta_C$ : 14.1 (C15), 22.6 (C2), 25.0 (C14), 28.8 (C12), 29.4 (C11), 31.6 (C3), 31.7 (C13), 32.5 (C10), 41.3 (C1), 41.6 (C4), 47.7 (C5), 130.0 (C9), 133.0 (C8), 211.4 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 2956, 2927, 2855, 1713, 1455, 1226, 975, 737 cm<sup>-1</sup>.

HRMS (EI) calc. for C<sub>14</sub>H<sub>24</sub>O 208.1827 found 208.1833.

**GC**: (Lipodex A);  $T_{inj} = 250 \,^{\circ}\text{C}$ ,  $T_{det} = 250 \,^{\circ}\text{C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 75 \,^{\circ}\text{C}$  (7 min), (5  $^{\circ}\text{C}$  min<sup>-1</sup>)  $t_f = 115 \,^{\circ}\text{C}$  (90 min), (0.7  $^{\circ}\text{C}$  min<sup>-1</sup>)  $t_f = 140 \,^{\circ}\text{C}$ : (*R*)-enantiomer:  $t_R = 49.19 \,\text{min}$ ; (*S*)-enantiomer:  $t_R = 49.95 \,\text{min}$ .

 $[\alpha]_{D}^{25}$ : +104.9 (*c* = 2.00, CHCl<sub>3</sub>).



Index	Name	Time [Min]	Quantity [% Area]	Height [uV]	Area [uV.Min]	Area % [%]
1	UNKNOWN	49.19	49.71	1674.2	570.0	49.712
2	UNKNOWN	49.95	50.29	1671.8	576.6	50.288
Total			100.00	3346.0	1146.5	100.000



Index	Name	Time	Quantity	Height	Area	Area %	
		[Min]	[% Area]	[uV]	[uV.Min]	[%]	
1	UNKNOWN	49.27	6.11	282.5	88.2	6.114	
2	UNKNOWN	50.07	93,89	3927.9	1354.7	93.886	
Total			100.00	4210.3	1442.9	100.000	

(S)-(E)-3-(hex-1-en-1-yl)cyclohexanone (2b)<sup>5</sup>



Prepared according to general procedure 1 from 1-hexyne (91  $\mu$ L, 0.75 mmol) and cyclohexenone (48  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 90% e.e. (62.2 mg, 69%, 0.345 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.58.

<sup>1</sup>**H** NMR (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.87 (3H, t, J = 7.0 Hz, C<sup>13</sup> $H_3$ ), 1.25–1.33 (4H, m, C<sup>11</sup> $H_2$  & C<sup>12</sup> $H_2$ ), 1.42–1.51 (1H, m, *c*-hex), 1.61–1.71 (1H, m, *c*-hex), 1.85–1.90 (1H, m, *c*-hex), 1.96–1.99 (2H, m, C<sup>10</sup> $H_2$ ), 2.01–2.06 (1H, m, *c*-hex), 2.14–2.28 (2H, m, *c*-hex), 2.30–2.41 (3H, m, *c*-hex). 5.34 (1H, dd, J = 15.0, 6.0 Hz, C<sup>8</sup>H), 5.41 (1H, dt, J = 15.0, 6.0 Hz, C<sup>9</sup>H).

<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $δ_C$ : 14.0 (C13), 22.2 (C12), 25.1 (C2), 31.6 (C11), 31.7 (C3), 32.3 (C10), 41.4 (C4), 41.7 (C1), 47.8 (C5), 130.1 (C9), 133 (C8), 211.8 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 2956, 2927, 2855, 1713, 1455, 1226, 975, 737 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>12</sub>H<sub>20</sub>O 180.1514, found 180.1511.

**GC**: (Lipodex A);  $T_{inj} = 250 \,^{\circ}\text{C}$ ,  $T_{det} = 250 \,^{\circ}\text{C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 75 \,^{\circ}\text{C}$  (7 min), (5  $^{\circ}\text{C}$  min<sup>-1</sup>)  $t_f = 115 \,^{\circ}\text{C}$  (90 min), (0.7  $^{\circ}\text{C}$  min<sup>-1</sup>)  $t_f = 140 \,^{\circ}\text{C}$ : (*R*)-enantiomer:  $t_R = 22.84 \,\text{min}$ ; (*S*)-enantiomer:  $t_R = 23.12 \,\text{min}$ .

 $[\alpha]_{D}^{25}$ : -7.8 (c = 2.00, CHCl<sub>3</sub>).



Index	Name	Time [Min]	Quantity [% Area]	Height [uV]	Area [uV.Min]	Area % [%]	Index	Name	Time [Min]	Quantity [% Area]	Height [uV]	Area [uV.Min]	Area % [%]
1	UNKNOWN	22.84	49.95	4681.3	500.5	49.951	1	UNKNOWN	22.84	4.60	1060.6	101.1	4.603
2	UNKNOWN	23.11	50.05	4570.5	501.5	50.049	2	UNKNOWN	23.12	95.40	19276.8	2094.6	95.397
Total			100.00	9251.8	1001.9	100.000	Total			100.00	20337.3	2195.6	100.000

(S)-(E)-3-(3-methylbuta-1,3-dien-1-yl)cyclohexanone (2c)<sup>6</sup>



Prepared according to general procedure 1 from 2-methyl-1-buten-3-yne (71  $\mu$ L, 0.75 mmol) and cyclohexenone (48  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 90% e.e. (57.5 mg, 70%, 0.35 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.35.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 1.49–1.59 (1H, m, *c*-hex), 1.64–1.76 (1H, m, *c*-hex), 1.83 (3H, s, C<sup>11</sup>**H**<sub>3</sub>), 1.92–1.97 (1H, m, *c*-hex), 2.04–2.10 (1H, m, *c*-hex), 2.20–2.30 (2H, m, *c*-hex), 2.36–2.40 (1H, m, *c*-hex), 2.43–2.48 (1H, m, *c*-hex), 2.52–2.61 (1H, m, *c*-hex), 4.92 (2H, app. s, C<sup>12</sup>**H**<sub>2</sub>), 5.58 (1H, dd, *J* = 16.0, 7.0 Hz, C<sup>8</sup>**H**), 6.14 (1H, d, *J* = 16.0 Hz, C<sup>9</sup>**H**).

<sup>13</sup>**C NMR** (CDCl<sub>3</sub>)  $\delta_{C}$ : 18.6 (C11), 25.0 (C2), 31.5 (C3), 41.3 (C4), 41.7 (C1), 47.4 (C5), 115.8 (C12), 132.0 (C8), 132.8 (C9), 141.6 (C10), 210.9 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3083, 2942, 1707, 1608, 1448 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>11</sub>H<sub>16</sub>O 164.1201, found 164.1199.

**GC**: (Lipodex A);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 250 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 50 \text{ °C}$ ,  $(1.0 \text{ °C min}^{-1}) t_f = 160$  (30 min): (*R*- enantiomer:  $t_R = 38.56 \text{ min}$ ; (*S*)-enantiomer:  $t_R = 38.70 \text{ min}$ .

 $[\alpha]_{D}^{25}$ : -5.2 (c = 2.00, CHCl<sub>3</sub>).



(S)-(E)-3-(2-(cyclohex-1-en-1-yl)vinyl)cyclohexanone (2d)



Prepared according to general procedure 1 from 1-ethynylcyclohexene (88  $\mu$ L, 0.75 mmol) and cyclohexenone (48  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 82% e.e. (40.8 mg, 40%, 0.20 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.31.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 1.50 - 1.54 (1H, m, *c*-hex), 1.56 - 1.68 (5H, m, *c*-hex), 1.89 - 1.96 (1H, m, *c*-hex), 2.06 - 2.11 (5H, m, *c*-hex), 2.18 - 2.31 (2H, m, *c*-hex), 2.32 - 2.39 (1H, m, *c*-hex), 2.41 - 2.46 (1H, m, *c*-hex), 2.49 - 2.55 (1H, m, *c*-hex), 5.46 (1H, dd, *J* = 16.0, 7.0 Hz, C<sup>8</sup>**H**), 5.69 (1H, app. s, C<sup>11</sup>**H**), 6.02 (1H, d, *J* = 16.0 Hz, C<sup>9</sup>**H**).

<sup>13</sup>**C NMR** (CDCl<sub>3</sub>)  $\delta_C$ : 22.6 (C15), 22.7 (C2), 24.7 (C14), 25.2 (C13), 25.9 (C12), 31.8 (C3), 41.2 (C4), 42.0 (C1), 47.8 (C5), 128.8 (C11), 129.0 (C9), 132.8 (C8), 135.3 (C10), 211.4 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3011, 2935, 2861, 2837, 1706, 1448 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>14</sub>H<sub>20</sub>O 204.1514, found 204.1522.

**GC**: (Lipodex A);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 250 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 75 \text{ °C}$  (7 min), (5 °C min<sup>-1</sup>)  $t_f = 115 \text{ °C}$  (90 min), (0.7 °C min<sup>-1</sup>)  $t_f = 140 \text{ °C}$ : (*R*)-enantiomer:  $t_R = 123.96 \text{ min}$ ; (*S*)- enantiomer:  $t_R = 125.36 \text{ min}$ .

[α]<sub>D</sub><sup>25</sup>: +5.5 (c = 2.00, CHCl<sub>3</sub>).



 $(S)-(E)-3-(2-cyclohexylvinyl)cyclohexanone (2e)^7$ 



Prepared according to general procedure 1 from cyclohexylacetylene (98  $\mu$ L, 0.75 mmol) and cyclohexenone (48  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 82% e.e. (52.6 mg, 51%, 0.255 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.42.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.98–1.08 (2H, m, *c*-hex), 1.11–1.31 (4H, m, *c*-hex), 1.63–1.71 (6H, m, *c*-hex), 1.86–1.93 (2H, m, *c*-hex), 2.00–2.07 (1H, m, *c*-hex), 2.14–2.21 (1H, m, *c*-hex), 2.23–2.29 (1H, m, *c*-hex), 2.32–2.36 (1H, m, *c*-hex), 2.37–2.45 (2H, m, *c*-hex), 5.28–5.40 (2H, m, C<sup>8</sup>**H** & C<sup>9</sup>**H**).

<sup>13</sup>**C NMR** (CDCl<sub>3</sub>)  $\delta_C$ : 25.1 (C2), 26.2 (C12 & C14), 26.3 (C13), 31.8 (C3), 32.2 (C11 & C15), 40.7 (C4), 41.4 (C10), 41.7 (C1), 47.9 (C5), 130.4 (C8), 135.9 (C9), 211.6 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3011, 2935, 2861, 2837, 1706, 1448 cm<sup>-1</sup>.

**HRMS** (EI): Calc. for C<sub>14</sub>H<sub>22</sub>O 206.1671, found 206.1667.

**GC**: (Lipodex A);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 250 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 50 \text{ °C}$ , (1.0 °C min<sup>-1</sup>)  $t_f = 160$  (30 min): (*R*)-enantiomer:  $t_R = 85.42 \text{ min}$ ; (*S*)-enantiomer:  $t_R = 85.83 \text{ min}$ .

**[**α]<sub>D</sub><sup>25</sup>: +3.6 (c=2.00, CHCl<sub>3</sub>).



## (S)-(E)-3-styrylcyclohexanone (2f)<sup>7</sup>



Prepared according to general procedure 1 from phenylacetylene (82  $\mu$ L, 0.75 mmol) and cyclohexenone (48  $\mu$ L, 0.50 mmol) to yield title compound as a colourless oil in 80% e.e. (51.9 mg, 52%, 0.26 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.36.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 1.60–1.67 (1H, m, *c*-hex), 1.70–1.80 (1H, m, *c*-hex), 1.99–2.06 (1H, m, *c*-hex), 2.07–2.14 (1H, m, *c*-hex), 2.27–2.45 (3H, m, *c*-hex), 2.51–2.56 (1H, m, *c*-hex), 2.66–2.70 (1H, m, *c*-hex), 6.16 (1H, dd, *J* = 16.0, 7.0 Hz, C<sup>8</sup>*H*), 6.39 (1H, d, *J* = 16.0 Hz, C<sup>9</sup>*H*), 7.21–7.24 (1H, m, C<sup>13</sup>*H*), 7.29–7.36 (4H, m, C<sup>11</sup>*H*, C<sup>12</sup>*H*, C<sup>14</sup>*H*, C<sup>15</sup>*H*).

<sup>13</sup>**C** NMR (CDCl<sub>3</sub>)  $δ_C$ : 25.1 (C2), 31.5 (C3), 41.4 (C1), 42.1 (C4), 47.5 (C5), 126.3 (C11 & C15), 127.5 (C13), 129.2 (C12 & C14), 129.7 (C9), 133.0 (C8), 137.2 (C10), 211.1 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3402, 3058, 3026, 2936, 2865, 1711, 1598, 1493, 1448, 1223 cm<sup>-1</sup>.

**HRMS** (EI): Calc. for C<sub>14</sub>H<sub>16</sub>O 200.1201, found 200.1203.

**HPLC**: (Chircel OD-H); eluent 2% isopropanol/hexane, 1.0 mL/min, 254 nm: (*S*)-enantiomer:  $t_R = 21.6 \text{ min}$ ; (*R*)-enantiomer:  $t_R = 23.3 \text{ min}$ .



[α]<sub>D</sub><sup>25</sup>: +85.5 (*c* = 2.00, CHCl<sub>3</sub>).

## (S, E)-3-methyl-3-(oct-1-en-1-yl)cyclohexanone (3a)<sup>8</sup>



Prepared according to general procedure 2 from 1-octyne (134  $\mu$ L, 1.4 mmol) and 3-methyl-cyclohexenone (55  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 94% e.e. (58.8 mg, 53%, 0.26 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.44.

<sup>1</sup>**H** NMR (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.87 (3H, t, J = 7.0 Hz, C<sup>15</sup>*H*<sub>3</sub>), 1.04 (3H, s, C<sup>16</sup>*H*<sub>3</sub>), 1.25–1.31 (8H, m, C<sup>11</sup>*H*<sub>2</sub>-C<sup>14</sup>*H*<sub>2</sub>), 1.57–1.62 (1H, m, *c*-hex), 1.66–1.72 (1H, m, *c*-hex), 1.79–1.86 (2H, m, *c*-hex), 1.94–1.99 (2H, m, *c*-hex), 2.14 (1H, d, J = 14.0 Hz, C<sup>5</sup>*H*), 2.19–2.32 (2H, m, C<sup>10</sup>*H*<sub>2</sub>), 2.42 (1H, dt, J = 14.0, 1.5 Hz, C<sup>5</sup>*H*), 5.28 (1H, d, J = 16.0 Hz, C<sup>8</sup>*H*), 5.35 (1H, dt, J = 16.0, 6.0 Hz, C<sup>9</sup>*H*).

<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta_C$ : 14.2 (C15), 22.3 (C2), 22.7 (C14), 28.2 (C16), 28.8 (C12), 29.5 (C11), 31.7 (C13), 32.8 (C10), 37.2 (C3), 40.9 (C4), 41.0 (C1), 52.4 (C5), 128.9 (C9), 137.7 (C8), 211.9 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 2956, 2927, 2855, 1713, 1455, 1226, 975, 737 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>15</sub>H<sub>26</sub>O 222.1984 found 122.1980.

**GC**: (octakis(2,6-di-*O*-methyl-3-*O*-pentyl- $\gamma$ -cyclodextrin);  $T_{inj} = 250 \,^{\circ}$ C,  $T_{det} = 250 \,^{\circ}$ C, flow = 2.0 mL min<sup>-1</sup>,  $t_i = 75 \,^{\circ}$ C (7 min), (5  $^{\circ}$ C min<sup>-1</sup>)  $t_f = 115 \,^{\circ}$ C (90 min), (0.7  $^{\circ}$ C min<sup>-1</sup>)  $t_f = 170 \,^{\circ}$ C (*R*)-enantiomer:  $t_R = 92.94 \,^{\circ}$ min; (*S*)-enantiomer:  $t_R = 98.54 \,^{\circ}$ min.

 $[\alpha]_{D}^{25}$ : +12.7 (*c* = 2.00, CHCl<sub>3</sub>).



(S)-(E)-3-(hex-1-en-1-yl)-3-methylcyclohexanone (3b)<sup>9</sup>



Prepared according to general procedure 1 from 1-hexyne (91  $\mu$ L, 0.75 mmol) and 3-methyl-cyclohexenone (55  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 92% e.e. (66.1 mg, 68%, 0.34 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.47.

<sup>1</sup>**H** NMR (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.90 (3H, t, J = 7.0 Hz,  $C^{14}H_3$ ), 1.06 (3H, s,  $C^{10}H$ ), 1.28–1.38 (4H, m,  $C^{12}H_2 \otimes C^{13}H_2$ ), 1.57–1.65 (1H, m, *c*-hex), 1.65–1.74 (1H, m, *c*-hex), 1.81–1.90 (2H, m, *c*-hex), 1.97–2.02 (2H, m, *c*-hex), 2.17 (1H, d, J = 14.0 Hz,  $C^5H$ ), 2.22–2.33 (2H, m,  $C^{11}H_2$ ), 2.44 (1H, dt, J = 14.0, 1.0 Hz,  $C^5H$ ), 5.30 (1H, d, J = 16.0 Hz,  $C^8H$ ), 5.37 (1H, dt, J = 16.0, 6.0 Hz,  $C^9H$ ).

<sup>13</sup>**C NMR** (CDCl<sub>3</sub>)  $\delta_C$ : 13.9 (C14), 22.1 (C2), 22.2 (C13), 28.1 (C10), 31.6 (C12), 32.4 (C11), 37.1 (C3), 40.7 (C4), 40.9 (C1), 52.4 (C5), 128.7 (C9), 137.5 (C8), 211.7 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 2956, 2927, 2855, 1713, 1455, 1226, 975, 737 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>13</sub>H<sub>22</sub>O 194.1671, found 194.1666.

**GC**: (octakis(2,6-di-*O*-methyl-3-*O*-pentyl- $\gamma$ -cyclodextrin);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 25 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 50 \text{ °C}$ , (1.0 °C min<sup>-1</sup>)  $t_f = 160$  (30 min): (*R*)-enantiomer:  $t_R = 36.30$  min; (*S*)-enantiomer:  $t_R = 38.22$  min.

Index
Name
Time
Quantity
Height
Area
Area
Main
%
Area
Area
%
Main
%
Main
%
Area
%
Main
%
Area
%
Main
%
Main
%
Main
%
Main
%
Main
%
Main</th

 $[\alpha]_{D}^{25}$ : +59.6 (*c* = 2.0, CHCl<sub>3</sub>).

#### (S)-(E)-3-methyl-3-(3-methylbuta-1,3-dien-1-yl)cyclohexanone (3c)



Prepared according to general procedure 1 from 2-methyl-1-buten-3-yne (71  $\mu$ L, 0.75 mmol)) and 3-methyl-cyclohexenone (55  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 98% e.e. (51.0 mg, 57%, 0.29 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.31.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 1.09 (3H, s, C<sup>13</sup>*H*<sub>3</sub>), 1.60–1.69 (1H, m, *c*-hex), 1.74–1.79 (1H, m, *c*-hex), 1.81 (3H, s, C<sup>12</sup>*H*<sub>3</sub>), 1.83–1.92 (2H, m, *c*-hex), 2.20 (1H, d, J = 14.0 Hz, C<sup>5</sup>*H*), 2.24–2.34 (2H, m, *c*-hex), 2.47 (1H, dt, J = 14.0, 1.0 Hz, C<sup>5</sup>*H*), 4.93 (2H, app. s, C<sup>11</sup>*H*<sub>2</sub>), 5.52 (1H, d, J = 16.0 Hz, C<sup>8</sup>H), 6.08 (1H, d, J = 16.0 Hz, C<sup>9</sup>H).

<sup>13</sup>**C** NMR (CDCl<sub>3</sub>)  $\delta_C$ : 18.7 (C12), 22.3 (C2), 22.7 (C13), 37.2 (C3), 41.0 (C1), 41.1 (C4), 52.5 (C5), 116.0 (C11), 130.7 (C9), 137.5 (C8), 141.7 (C10), 211.4 (C6).

**IR** (CHCl<sub>3</sub>)  $v_{max}$ : 3010, 2959, 2929, 2872, 1704, 1455, 1378, 972, 892 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>12</sub>H<sub>18</sub>O 178.1358, found 178.1356.

**GC**: (octakis(2,6-di-O-methyl-3-O-pentyl- $\gamma$ -cyclodextrin);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 250 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 50 \text{ °C}$ , (1.0 °C min<sup>-1</sup>)  $t_f = 160$  (30 min): (*R*)-enantiomer:  $t_R = 66.51$  min; (*S*)-enantiomer:  $t_R = 67.85$  min.

 $[\alpha]_{D}^{25}$ : +29.0 (*c* = 2.00, CHCl<sub>3</sub>)



## (S)-(E)-3-(2-cyclopropylvinyl)-3-methylcyclohexanone (3g)



Prepared according to general procedure 1 from cyclopropylacetylene (71  $\mu$ L, 0.75 mmol) and 3-methyl-cyclohexenone (55  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 94% e.e. (26.3 mg, 30%, 0.15 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.42.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.29–0.32 (2H, m, *c*-propyl), 0.63–0.67 (2H, m, *c*-propyl), 1.03 (3H, s, C<sup>13</sup>*H*<sub>3</sub>), 1.24–1.34 (1H, m, C<sup>10</sup>*H*), 1.55–1.61 (1H, m, *c*-hex), 1.66–1.71 (1H, m, *c*-hex), 1.80–1.87 (2H, m, *c*-hex), 2.13 (1H, d, *J* = 14.0 Hz, C<sup>5</sup>*H*), 2.17–2.31 (2H, m, *c*-hex), 2.37 (1H, dt, *J* = 14.0, 1.5 Hz, C<sup>5</sup>*H*), 4.86 (1H, dd, *J* = 16.0, 8.5 Hz, C<sup>9</sup>*H*), 5.38 (1H, d, *J* = 16.0 Hz, C<sup>8</sup>*H*).

 $^{13}\text{C}$  NMR (CDCl<sub>3</sub>)  $\delta_{\text{C}}$ : 6.72 (C11 & C12), 13.9 (C10), 22.3 (C2), 28.0 (C13), 37.2 (C3), 40.8 (C4), 41.0 (C1), 52.5 (C5), 132.3 (C9), 136.4 (C8), 211.8 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3038, 3010, 2959, 2873, 1704, 1454, 1426, 1313, 1291, 1241, 968 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>12</sub>H<sub>18</sub>O 178.1358 found 178.1361.

**GC**: (octakis(2,6-di-*O*-methyl-3-*O*-pentyl- $\gamma$ -cyclodextrin);  $T_{inj} = 250 \,^{\circ}\text{C}$ ,  $T_{det} = 250 \,^{\circ}\text{C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 50 \,^{\circ}\text{C}$ , (1.0  $^{\circ}\text{C} \,^{\text{min}^{-1}}$ )  $t_f = 160$  (30 min): (*R*)-enantiomer:  $t_R = 69.64$  min; (*S*)-enantiomer:  $t_R = 70.86$  min.

 $[\alpha]_{D}^{25}$ : +37.4 (*c* = 2.00, CHCl<sub>3</sub>).



## (S)-(E)-3-ethyl-3-(oct-1-en-1-yl)cyclohexanone (4a)



Prepared according to general procedure 2 from 1-octyne (134  $\mu$ L, 0.75 mmol) and 3-ethyl-cyclohexenone (59  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 88% e.e. (70.9 mg, 60%, 0.29 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.50.

<sup>1</sup>**H** NMR (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.78 (3H, t, J = 7.5 Hz, C<sup>11</sup>*H*<sub>3</sub>), 0.87 (3H, t, J = 7.0 Hz, C<sup>17</sup>*H*<sub>3</sub>), 1.19–1.32 (8H, m, C<sup>13</sup>*H*<sub>2</sub>-C<sup>16</sup>*H*<sub>2</sub>), 1.34–1.40 (2H, m, C<sup>10</sup>*H*<sub>2</sub>), 1.60–1.69 (2H, m, *c*-hex), 1.76–1.86 (2H, m, *c*-hex), 1.96–2.02 (2H, m, *c*-hex), 2.10 (1H, d, J = 14.0 Hz, C<sup>5</sup>*H*), 2.16–2.32 (2H, m, C<sup>12</sup>*H*<sub>2</sub>), 2.49 (1H, d, J = 14.0 Hz, C<sup>5</sup>*H*), 5.12 (1H, d, J = 16.0 Hz, C<sup>8</sup>*H*), 5.31 (1H, dt, J = 16.0, 7.0 Hz, C<sup>9</sup>*H*).

<sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta_C$ : 7.9 (C11), 14.1 (C17), 21.7 (C2), 22.6 (C16), 28.7 (C14), 29.5 (C13), 31.7 (C10), 32.9 (C15), 34.2 (C3), 35.3 (C12), 41.2 (C1), 44.1 (C4), 49.8 (C5), 131.1 (C9), 135.3 (C8), 211.9 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3038, 3010, 2959, 2873, 1704, 1454, 1426, 1313, 1291, 1241, 968 cm<sup>-1</sup>

**HRMS** (EI): calc. for C<sub>16</sub>H<sub>28</sub>O 236.2140 found 236.2138.

**GC**: (octakis(2,6-di-*O*-methyl-3-*O*-pentyl- $\gamma$ -cyclodextrin);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 250 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 50 \text{ °C}$ , (1.0 °C min<sup>-1</sup>)  $t_f = 160$  (30 min): (*R*)-enantiomer:  $t_R = 100.24$  min; (*S*)-enantiomer:  $t_R = 101.02$  min.

100 101 100 101 Name Index Name Time Quant [Min] [% Are Height Area [uV] [uV.Min Time Height Area [uV] [uV.Min] [Min] [% Are UNKNOWN 100.31 UNKNOWN 101.08 UNKNOWN 100.24 UNKNOWN 101.02 15500.3 15696.7 6563.3 5.63 94.37 9764.9 50.483 100.00 10417.5 4276.9 100.000 31197.0 13001.0 100.000

[α]<sub>D</sub><sup>25</sup>: +69.1 (*c*=2.00, CHCl<sub>3</sub>).

(S)-(E)-3-ethyl-3-(oct-1-en-1-yl)cyclohexanone (4b)<sup>10</sup>



Prepared according to general procedure 1 from 1-hexyne (71  $\mu$ L, 0.75 mmol)) and 3-ethyl-cyclohexenone (59  $\mu$ L, 0.5 mmol) to yield title compound as a colourless oil in 96% e.e. (47.9 mg, 46%, 0.23 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.55.

<sup>1</sup>**H** NMR (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.80 (3H, t, J = 7.0 Hz, C<sup>11</sup>*H*<sub>3</sub>), 0.90 (3H, t, J = 7.0 Hz, C<sup>15</sup>*H*<sub>3</sub>), 1.25–1.36 (4H, m, C<sup>13</sup>*H*<sub>2</sub> & C<sup>14</sup>*H*<sub>2</sub>), 1.36–1.42 (2H, m, C<sup>10</sup>*H*<sub>2</sub>), 1.60–1.71 (2H, m, *c*-hex), 1.79–1.90 (2H, m, *c*-hex), 2.00–2.06 (2H, m, *c*-hex), 2.13 (1H, d, J = 14.0 Hz, C<sup>5</sup>*H*), 2.18–2.33 (2H, m, C<sup>12</sup>*H*<sub>2</sub>), 2.49 (1H, dt, J = 14.0, 1.5 Hz, C<sup>5</sup>*H*), 5.14 (1H, d, J = 16.0 Hz, C<sup>8</sup>*H*), 5.34 (1H, dt, J = 16.0, 6.5 Hz, C<sup>9</sup>*H*).

<sup>13</sup>**C** NMR (CDCl<sub>3</sub>)  $\delta_{C}$ : 7.8 (C11), 13.9 (C15), 21.7 (C2), 22.1 (C14), 31.7 (C10), 32.6 (C13), 34.2 (C3), 35.3 (C12), 41.2 (C1), 44.1 (C4), 49.8 (C5), 131.0 (C9), 135.3 (C8), 211.9 (C6).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3038, 3010, 2959, 2873, 1704, 1454, 1426, 1313, 1291, 1241, 968 cm<sup>-1</sup>.

**HRMS** (EI): calc. for C<sub>14</sub>H<sub>24</sub>O 208.1827 found 208.1820.

**GC**: (octakis(2,6-di-*O*-methyl-3-*O*-pentyl- $\gamma$ -cyclodextrin);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 250 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 50 \text{ °C}$ , (1.0 °C min<sup>-1</sup>)  $t_f = 160$  (30 min): (*R*)-enantiomer:  $t_R = 81.01$  min; (*S*)-enantiomer:  $t_R = 82.19$  min.

 $[\alpha]_{D}^{25}$ : +31.8 (*c* = 2.00, CHCl<sub>3</sub>).



#### (E)-4-methyldec-5-en-2-one (5)



Prepared according to general procedure 1 from 1-hexyne (71  $\mu$ L, 0.75 mmol), 3-penten-2-one (49  $\mu$ L, 0.5 mmol), trimethylaluminium (0.37 mL, 0.75 mmol) and tricyclohexylphosphine (24.5 mg, 0.075 mmol) to yield title compound as a yellow oil (18.5 mg, 22%, 0.11 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.64.

<sup>1</sup>**H** NMR (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.58 (3H, t, J = 7.0 Hz,  $C^{12}H_3$ ), 0.99 (3H, d, J = 6.5 Hz,  $C^6H_3$ ), 1.25-1.34 (4H, m,  $C^{10}H_2 \otimes C^{11}H_2$ ), 1.96 (2H, app q, J = 6.0 Hz,  $C^9H_2$ ), 2.11 (3H, s,  $C^3H_3$ ), 2.33 (1H, dd, J = 15.5, 7.0 Hz,  $C^4H$ ), 2.42 (1H, dd, J = 15.5, 7.0 Hz,  $C^7H$ ), 5.30 (1H, dd, J = 15.5, 7.0 Hz,  $C^7H$ ), 5.40 (1H, dt, J = 15.5, 6.0 Hz,  $C^8H$ ).

<sup>13</sup>**C NMR** (CDCl<sub>3</sub>) δ<sub>C</sub>: 14.1 (C12), 20.7 (C6), 22.3 (C11), 30.7 (C5), 31.8 (C3), 32.9 (C9), 51.3 (C4), 129.6 (C8), 134.4 (C7), 208.6 (C2).

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3010, 2961, 2930, 2873, 1710, 1457, 1360, 971 cm<sup>-1</sup>.

**HRMS** (ESI<sup>+</sup>): calc. for  $C_{14}H_{24}O$  219.1597 found [M+MeOH+H<sub>2</sub>O+H<sup>+</sup>] 219.1717.

**GC:** (octakis(6-*O*-pentyl-2,3-di-*O*-methyl- $\gamma$ -cyclodextrin);  $T_{inj} = 250 \text{ °C}$ ,  $T_{det} = 250 \text{ °C}$ , flow = 2.0 mL min<sup>-1</sup>,  $t_i = 70 \text{ °C}$ , (45 min)(20 °C min<sup>-1</sup>)  $t_f = 170$  (10 min): enantiomer 1:  $t_R = 29.37$  min; enantiomer 2:  $t_R = 30.39$  min.

Maximum 39% enantioselectivity was obtained in asymmetric runs broadly analogous to Table 1 but due to the low chemical yield (11%) this was not further optimised.

#### (E)-4-isopropyldec-5-en-2-one (6)



Prepared according to general procedure 1 from 1-hexyne (71  $\mu$ L, 0.75 mmol), 5-methyl-3-hexen-2-one (66  $\mu$ L, 0.5 mmol), trimethylaluminium (0.37 mL, 0.75 mmol) and tricyclohexylphosphine (24.5 mg, 0.075 mmol) to yield title compound as a yellow oil (18.5 mg, 22%, 0.11 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.60.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.82-0.92 (9H, m, C<sup>9</sup>*H*<sub>3</sub>, C<sup>10</sup>*H*<sub>3</sub>, C<sup>14</sup>*H*<sub>3</sub>), 1.19-1.34 (4H, m, C<sup>12</sup>*H*<sub>2</sub> & C<sup>13</sup>*H*<sub>2</sub>), 1.54-1.60 (1H, m, C<sup>6</sup>*H*), 1.97 (2H, app q, *J* = 6.5 Hz, C<sup>11</sup>*H*<sub>2</sub>), 2.10 (3H, s, C<sup>3</sup>*H*<sub>3</sub>), 2.31-2.47 (3H, m, C<sup>4</sup>H<sub>2</sub> & C<sup>5</sup>*H*), 5.19 (1H, dd, *J* = 15.0, 8.5 Hz, C<sup>7</sup>*H*), 5.38 (1H, dt, *J* = 15.0, 6.5 Hz, C<sup>8</sup>*H*).

<sup>13</sup>**C NMR** (CDCl<sub>3</sub>)  $\delta_C$ : 14.1 (C14), 18.9 (C10), 20.6 (C9), 22.3 (C13), 30.7 (C5), 31.8 (C3), 32.0 (C12), 32.4 (C11), 45.2 (C6), 47.3 (C4), 130.3 (C8), 132.5 (C7), 209.3 (C2).

**IR** (CHCl<sub>3</sub>)  $v_{max}$ : 3010, 2961, 2930, 2873, 1706, 1466, 1369, 1358, 973 cm<sup>-1</sup>.

**HRMS** (ESI): calc. for C<sub>13</sub>H<sub>24</sub>O 196.1827, found [M+H] 197.1907.

#### (E)-3-methyl-3-(2-(trimethylsilyl)vinyl)cyclohexanone (8)



Prepared according to general procedure 1 from trimethylsilylacetylene (104  $\mu$ L, 0.75 mmol) and 3-methyl-cyclohexenone (55  $\mu$ L, 0.5 mmol) trimethylaluminium (0.37 mL, 0.75 mmol) and tricyclohexylphosphine (24.5 mg, 0.075 mmol) to yield title compound as a colourless oil (21.1 mg, 20%, 0.10 mmol) **R**<sub>f</sub> (pentane/diethyl ether 4:1) 0.36.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.06 (9H, s, Si(C**H**<sub>3</sub>)<sub>3</sub>), 1.05 (3H, s, C<sup>9</sup>**H**<sub>3</sub>), 1.56-1.62 (1H, m, c-hex), 1.69-1.85 (3H, m, c-hex), 2.16 (1H, d, *J* = 14.0 Hz, C<sup>5</sup>H), 2.20-2.30 (2H, m, c-hex), 2.47 (1H, dt, *J* = 14.0, 1.0 Hz, C<sup>5</sup>**H**), 5.60 (1H, d, *J* = 19.0 Hz, C<sup>10</sup>**H**), 5.88 (1H, d, *J* = 19.0 Hz, C<sup>8</sup>**H**).

<sup>13</sup>**C NMR** (CDCl<sub>3</sub>) δ<sub>C</sub>: 1.06 (Si(*C*H<sub>3</sub>)<sub>3</sub>), 22.2 (C9), 27.1 (C2), 36.5 (C3), 41.0 (C1), 42.9 (C4), 51.8 (C5), 127.1 (C10), 153.3 (C8), 211.6 (C6).

**IR** (CHCl<sub>3</sub>)  $v_{max}$ : 3010, 2958, 1705, 1612, 1248, 867, 841 cm<sup>-1</sup>.

**HRMS** (EI): Calculated for C<sub>12</sub>H<sub>22</sub>OSi [M+] 210.1440, found 210.1436.

#### Footnote tetracyclic compound



Racemic tetracycle was identified in early optimisation studies using CuTC/PCy<sub>3</sub> or **L1** as the major mass balance element. It was isolatedwas purified by flash chromatography (pentane/diethyl ether 4:1)  $\mathbf{R}_{f}$  0.28.

<sup>1</sup>**H NMR** (CDCl<sub>3</sub>)  $\delta_{\text{H}}$ : 0.89 (3H, t, J = 7.0 Hz, C $H_3$ ), 0.99–1.18 (3H, m), 1.27-1.32 (8H, m, C $H_2$ ), 1.41–1.54 (3H, m), 1.66–2.45 (16H, m), 2.50 (1H, d, J = 10.5 Hz), 2.61 (1H, m), 2.97 (1H, app t, J = 11.0 Hz), 4.42 (1H, s), 5.20 (1H, app dd, J = 15.0, 8.0 Hz), 5.45 (1H, dt, J = 15.0, 7.0 Hz).

 $^{13}\textbf{C}$  NMR (CDCl<sub>3</sub>)  $\delta_{\text{C}}$ : 14.2, 20.6, 20.7, 22.7, 27.6, 28.8, 29.8, 31.8, 32.8, 34.4. 38.1, 41.9, 45.5, 55.1, 55.9, 75.5, 130.7, 134.8, 213.7, 219.3 ppm.

**IR** (CHCl<sub>3</sub>) v<sub>max</sub>: 3598, 3546, 3047. 3005, 2976, 2950, 2925, 2862, 1705, 1478, 1436, 1323, 1118 cm<sup>-1</sup>.

**HRMS** (ESI): calc. for [M+Na]<sup>+</sup> 422.2989 found 422.2982.









- 50000 - 40000 - 30000 - 20000 - 10000 - 0 - - 10000 Electronic Supplementary Material (ESI) for Chemical Communications This journal is C The Royal Society of Chemistry 2014

















Electronic Supplementary Material (ESI) for Chemical Communications This journal is The Royal Society of Chemistry 2014

















#### References

- <sup>1</sup> P. Kraft and K. Popaj, *Eur. J. Org. Chem.*, 2008, 4806–4814.
- (a) Phosporamidates: L. A. Arnold, R. Imbos, A. Mandoli, A. H. M. de Vries, R. Naasz and B. L. Feringa, *Tetrahedron*, 2000, **56**, 2865-2878. (b) SimplePhos ligands: D. Müller, L. Guénée and A. Alexakis, *Eur. J. Org. Chem.*, 2013, 6335–6343.
- <sup>3</sup> H. Gottlieb, V. Kotlyar and A. Nudelman, *J. Org. Chem.*, 1997, **62**, 7512–7515.
- <sup>4</sup> S. Oi, T. Sato and Y. Inoue, *Tetrahedron Lett.* 2004, **45**, 5051-5056.
- <sup>5</sup> M .K. Brown and E. J. Corey, *Org. Lett.* 2010, **12**, 172–175.
- <sup>6</sup> Y. Nakao, J. Chen, H. Imanaka, T. Hiyama, Y. Ichikawa, W-L. Duan, R. Shintani, and T. Hayashi, *J. Am. Chem. Soc.*, 2007, **129**, 9137-9143.
- <sup>7</sup> K. S. Lee and A. H. Hoveyda, *J. Org. Chem.*, 2009, **74**, 4455–4462.
- <sup>8</sup> T. L. May, J. A. Dabrowski and A. H. Hoveyda, *J. Am. Chem. Soc.*, 2011, **133**, 736–739.
- <sup>9</sup> C. Hawner, K. Li, V. Cirriez and A. Alexakis, *Angew. Chem. Int. Ed.*, 2008, **47**, 8211–8214.
- <sup>10</sup> D. Müller, M. Tissot, A. Alexakis, *Org. Lett*, **2011**, *13*, 3040–3043.